VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a report published on Wednesday. The firm issued a sell rating on the stock.

Several other research firms also recently commented on VNRX. Benchmark reissued a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital restated a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research note on Tuesday, March 4th.

VolitionRx Stock Performance

Shares of VNRX opened at $0.56 on Wednesday. The company’s 50 day moving average price is $0.61 and its 200 day moving average price is $0.65. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.02. The company has a market capitalization of $51.99 million, a PE ratio of -1.56 and a beta of 1.09.

Hedge Funds Weigh In On VolitionRx

Several large investors have recently bought and sold shares of the stock. Two Sigma Securities LLC acquired a new position in shares of VolitionRx in the 4th quarter valued at $29,000. Millennium Management LLC acquired a new position in shares of VolitionRx in the 4th quarter valued at $36,000. Northern Trust Corp raised its stake in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after buying an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. raised its stake in shares of VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.